Podcast Cruzamento André Correia e Daniel Guedelha
-
- Tecnologia
-
🇵🇹 O Podcast onde os temas da Tecnologia e Saúde se cruzam para criar um espaço de debate aberto e inovador, através de entrevistas descontraídas, mas com conteúdos importantes e atuais. Ambicionamos que este podcast sirva como fonte de inovação e de criatividade para os nossos ouvintes.
🇺🇸 🇬🇧 The Cruzamento Podcast is where Technology and Health intersect to create an open and innovative debate, through relevant, current and informal interviews with recognised thought leaders. Our ambition is that this podcast becomes a source of innovation and creativity for all our listeners.
-
78: Alan Triggs: Leadership, Longevity and the AI Revolution [EN]
In this episode of Cruzamento Podcast, hosts André Correia and Daniel Guedelha explore the intersections of technology, healthcare, and leadership with Alan Triggs, Chief Digital Officer for Nokia. They delve into the impact of AI on industries, discussing the evolution of AI, its role in job creation and displacement, and its potential impact on healthcare and education. Alan shares insights on data management, privacy concerns, and the role of regulation in technology. The discussion extends to the personal experiences, touching on longevity, wellness, and the importance of sleep hygiene in the digital age. Alan also shares experiences from relocating to Portugal and Nokia's investment in the country.
Tune in to explore these topics and more in this insightful episode.
Alan Triggs is the Chief Digital Officer for Nokia globally, with responsibility for Nokia’s information technology (IT) and digitalisation initiatives. In this role, he is responsible for the global infrastructure for enterprise computing, networking, and end-user services, and enterprise applications covering R&D, services, supply, and financial & commercial systems. He is responsible for number of digital transformation initiatives including a company-wide cloud transformation, the modernisation of core application systems, and the corporate data strategy. Alan has held a number of leadership roles in IT; Telecom and has lived and worked in in seven countries across Africa, Europe and the US. He is currently based out of Portugal.
Other relevant references | Outras referências relevantes:
Blueprint (by Bryan Johnson)
Contacts | Contactos:
CruzamentoPodcast.com
cruzamentopodcast@gmail.com
LinkedIN: Cruzamento
Twitter: @cruzamentofm
Facebook: @podcastcruzamento
Instagram: @cruzamentopodcast
YouTube: Podcast Cruzamento
Episode edited by João Cunha Studios -
77: Luís Oliveira: Inovações no tratamento da Doença de Parkinson com a The Michael J. Fox Foundation [PT]
Neste episódio do Podcast CRUZAMENTO, André Correia e Daniel Guedelha dialogam com Luís Oliveira, Senior Associate Director Research Programs na The Michael J. Fox Foundation, abordando a missão inspiradora da fundação, o impacto global das doenças neurodegenerativas em saúde e economia, e estratégias eficazes para mitigar riscos na Doença de Parkinson.
Luis Miguel Oliveira is a Senior Associate Director of Research Programs at The Michael J. Fox Foundation and the Founder of v-ATPase Alliance for rare diseases due to v-ATPase defects.
Luís is an expert in the field of Parkinson's disease research and investment with more than 15 years of experience in the neurologic diseases space. Currently, he holds the position of Senior Associate Director of Research Programs at The Michael J. Fox Foundation, where he leads various efforts for therapeutic and biomarker development in priority genetic targets in Parkinson's disease accounting for over $30 million in executed projects. Additionally, Luis Miguel Oliveira is a founder of the v-ATPase Alliance, an organization aimed at connecting families affected by rare diseases related to v-ATPase with the research and medical communities to further advance therapeutic development.
With a strong commitment to advance novel treatments from the bench to bedside, Luis Miguel Oliveira serves as a Review Editor for Frontiers in Neurology, Neuroscience and Psychiatry, and as an Investment Advisor for Portugal Ventures, where he leverages his expertise to guide investment decisions in promising ventures.
Recently, Luis Miguel Oliveira had an integral contribution to a landmark study that validated the first biomarker for Parkinson's disease diagnosis. This significant achievement was reported in Lancet Neurology with broader international media coverage and is changing the Parkinson's research and drug development fields by enabling an objective characterization of the disease based on its biological features.
Luis Miguel Oliveira's educational background includes a degree in Biochemistry from the Faculty of Sciences of Lisbon University. He further pursued his academic journey with a PhD in Molecular Biophysics from the same institution. During his postdoctoral research experience, he conducted his studies at renowned institutions such as the Max Planck Institute for Biophysical Chemistry in Germany and Columbia University in New York.
Other relevant references | Outras referências relevantes:
v-ATPase Alliance (website)
The Michael J. Fox Foundation (website)
Contacts | Contactos:
CruzamentoPodcast.com
cruzamentopodcast@gmail.com
LinkedIN: Cruzamento
Twitter: @cruzamentofm
Facebook: @podcastcruzamento
Instagram: @cruzamentopodcast
YouTube: Podcast Cruzamento -
76: Stefan Buttigieg: Intersecting cultural transformation and healthcare [EN]
In today's CRUZAMENTO Podcast, André Correia e Daniel Guedelha talked with Stefan Buttigieg, about the impact of AI on healthcare. Highlights include AI's potential in public health, data sharing challenges in Europe, AI projects in Malta, and the importance of equity and ethical data handling in healthcare.
Dr. Stefan Buttigieg is a Specialist in Public Health Medicine working in the Ministry for Health in Malta !🇲🇹
He is a Keynote Speaker with 50+ public speaking engagements track record and an avid content creator!📱🎙️.
He is the manager of the National Contact Point of eHealth and lectures at the University of Malta on the topics of Digital Health, Social Media in Healthcare and Digital Therapeutics.
He is the Vice-President of the EUPHA Section on Digital Health and is a WFPHA Governing Council Member.
Dr Buttigieg is on a mission to enable equitable Digital Health and Health Data for All ensuring that no one is left behind
Other relevant references | Outras referências relevantes:
Stefan Buttigieg (Website)
Yuval Noah Harari argues that AI has hacked the operating system of human civilisation
Yuval Noah Harari at the Frontiers Forum - AI and the future of humanity
Contacts | Contactos:
CruzamentoPodcast.com
cruzamentopodcast@gmail.com
LinkedIN: Cruzamento
Twitter: @cruzamentofm
Facebook: @podcastcruzamento
Instagram: @cruzamentopodcast
YouTube: Podcast Cruzamento -
75: Ana França & António Gonçalves: Revolutionizing Organ Donation Through Technology [EN]
In today's CRUZAMENTO Podcast, André Correia and Daniel Guedelha talked with Ana França and António Gonçalves. They delved into Health, Technology, and Sustainability, with a focus on transplantation, common transplant types and their impact, insights from companies expanding globally, and future trends in transplantation technology. The discussion showcases TransplantHUB's role in harnessing these advancements for patient benefit.
Meet Ana França, a highly skilled and dedicated organ donation and transplantation management expert. With over a decade of experience, Ana has been instrumental in transforming Portugal's organ donation and transplantation system, improving patient outcomes, and increasing access to life-saving procedures for those in need. Her global initiatives in developing digital transplantation registries have revolutionized how organ donation and transplantation procedures are managed worldwide, earning her recognition as a leader in her field. Ana's expertise in organ donation and transplantation and her passion for improving patient outcomes make her an invaluable asset to managing organ donation and transplantation.
With over 25 years of experience in IT Services, António Gonçalves brings together a vast experience in business analysis with a comprehensive technical area know-how in diverse industries, including Healthcare, Insurance, Local Government, Industry, and Logistics. This experience, and above all, the unquestionable ability to apply it in various sectors, allowed him not only to create reasonable conceptual solutions but, above all, practical solutions amenable to a linear technical implementation. His adaptability to a diverse audience, both functional and technical, has allowed him to design innovative products and, more importantly, create practical, innovative solutions with a linear technical implementation.
Other relevant references | Outras referências relevantes:
Transplant Hub (website)
Contacts | Contactos:
CruzamentoPodcast.com
cruzamentopodcast@gmail.com
LinkedIN: Cruzamento
Twitter: @cruzamentofm
Facebook: @podcastcruzamento
Instagram: @cruzamentopodcast
YouTube: Podcast Cruzamento -
74: Patrícia Calado: Qual a estratégia para o futuro da investigação? [PT]
Neste episódio do Podcast CRUZAMENTO, André Correia e Daniel Guedelha conversam com Patrícia Calado sobre estratégias de inovação e pesquisa na saúde, bem como a necessidade de avaliar adequadamente os investimentos públicos nesta área. A interdisciplinaridade na pesquisa médica é também destacada como crucial para solucionar problemas complexos de saúde.
Patrícia Calado is a results-driven professional dedicated to accelerating positive impact through the uptake of innovation into healthcare. Her career was built on collaborative work with healthcare institutions, industry, and research organizations all over the country. Currently she's a member of the Board at NOVA Medical School (NMS), as Vice-Dean for Research, and she's responsible for developing and implementing the faculty’s research and innovation strategy, in close articulation to the Dean.
Previously she worked for different innovation and funding agencies in Portugal as the National Contact Point and Delegate for Health in the EU Research and Innovation Programme (2015-2022). Between 2020 and 2022 she was a member of the Board at the Agency for Clinical Research and Biomedical Innovation (AICIB), were she led the international strategy of the Agency and set up the team of National Contact Points and Delegates for Health.
She has 25+ years of experience in the fields of Health and Life Sciences with experience in the coordination of multi-disciplinary teams in the context of academia, SME, and governmental agencies.
She's driven by inspiring and motivating people to achieve a shared vision and goals. During her career she implemented processes of transformational leadership by encouraging innovation and empowering her teams to take risks and learn from mistakes, while creating a culture of trust, openness, and learning in the organization.
She has a PhD in Biomedical Sciences from the Faculty of Medicine of the University of Lisbon and a degree in Biology from the Faculty of Sciences and Technology of the University of Coimbra.
Other relevant references | Outras referências relevantes:
NOVA Medical School (NMS) (website)
Agency for Clinical Research and Biomedical Innovation (AICIB) (website)
Contacts | Contactos:
CruzamentoPodcast.com
cruzamentopodcast@gmail.com
LinkedIN: Cruzamento
Twitter: @cruzamentofm
Facebook: @podcastcruzamento
Instagram: @cruzamentopodcast
YouTube: Podcast Cruzamento -
73: Ron DePinho: Pioneering Cancer Combat with Tech Breakthroughs [EN]
In today's CRUZAMENTO Podcast, André Correia e Daniel Guedelha talked with Ron DePinho who delves into his contributions to cancer research and innovation, emphasizing the transformative potential of biotechnology in this critical field. His work is dedicated to advancing our understanding of cancer biology, enabling the development of more precise diagnostic tools and targeted therapies. Through his efforts, he aims to revolutionize the way we approach cancer treatment, with the ultimate goal of improving patient outcomes and quality of life. Additionally, Ron de Pinho actively engages in educating influential figures such as the President of the United States and the Pope, advocating for policies that support the advancement of biotechnology in healthcare and sustainability. His dedication to both research and advocacy solidifies his position as a leading figure in the biotech industry.
Ronald A. DePinho, M.D. is currently past president and distinguished university professor of The University of Texas MD Anderson Cancer Center. His research has focused on the fundamental mechanisms driving cancer and aging and the clinical application of such knowledge to prevent and treat disease.
Dr. DePinho studied biology at Fordham University, where he graduated class salutatorian, and received his M.D. degree with distinction in microbiology and immunology from the Albert Einstein College of Medicine. He performed his residency and postdoctoral training at Columbia-Presbyterian Medical Center.
Dr. DePinho’s independent career began at Einstein as the Feinberg Senior Faculty Scholar in Cancer Research and an ACS Research Professor. He then joined the Dana-Farber Cancer Institute and Harvard Medical School where he was the founding Director of the Belfer Institute for Applied Cancer Science and a Professor of Medicine and Genetics at Harvard. As president of MD Anderson, Dr. DePinho conceived and launched the Moon Shots Program, a goal-oriented comprehensive effort designed to accelerate declines in cancer incidence and mortality. This initiative has yielded practice-changing advances in cancer and inspired the national cancer moonshot under President Biden. He also elevated MD Anderson’s research and graduate programs, recruited many world class faculty including National Academy Members and its first Nobel Prize. To improve cancer care beyond MD Anderson, he launched and assembled a network of cancer institutions in 24 countries, reaching one-third of the human population.
As a researcher, he has published over 400 articles, books and chapters that have advanced our understanding of cancer, aging and degenerative disorders which have led to clinical advances including new cancer drugs and diagnostics. His most notable discoveries include elucidation of the core molecular pathway for aging, determination of the basis for the intimate link between advancing age and increased epithelial cancer incidence, establishment of the central role of telomeres in cancer genome instability, discovery of Sin3 and linkage of sequence specific transcription factors and chromatin regulators, demonstration that aging itself can be reversed which led to new therapeutic strategies for aging and age-related diseases including Alzheimer’s Disease. To translate these basic discoveries, he founded 9 private and publicly traded biotechnology companies and served as an advisor or director for biotech and large biopharma companies focused on oncology. His public service includes advisory and directorship roles for AACR and the NIH, as well as the Vatican and several countries. He is chairman and co-founder a non-profit, OPA Health (previously, Unite to Prevent Cancer) whose mission is disease prevention in underserved communities. As an advocate, he was a key instigator in the bipartisan bill raising the age of tobacco purchase to 21 (T21) and the bipartisan Cures Act. He is Vice Chair of the BOD for Act For NIH, a non-profit advocacy organ
Críticas de clientes
Fantástico podcast!!!
Excelente iniciativa do Daniel e do André!! Os meus parabéns e o meu muito obrigada por toda a partilha feita através de convidados muito diversificados que acrescentam perspectivas muito ricas sobre o cruzamento destas duas realidades.
Obrigado pela vossa partilha
O vosso podcast é excelente. Foi a primeira formação interna do ano na Farmácia onde trabalho. Não parem.
João
Saude e Digital e Portugal
Excelente podcast. Para quem está interessado na área da saude e na sua relação com a área digitial este será o podcast para seguirem e subscrever. Além disso estou ansioso para ouvir os convidados relacionados com estas duas áreas.